Securities Code: 002422 Securities Abbreviation: Kelun Pharmaceutical Announcement No.: 2026-022
Sichuan Kelun Pharmaceutical Co., Ltd. Announcement of Resolutions of the 12th Meeting of the 8th Board of Directors
The Company and all members of the Board of Directors guarantee the content of the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
The notice of the 12th meeting of the 8th Board of Directors of Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Kelun Pharmaceutical") was delivered to all directors and senior management by telephone and email on March 20, 2026. The 12th meeting of the 8th Board of Directors was held on April 1, 2026, at the headquarters of Kelun Pharmaceutical, in a combination of on-site and teleconference format. Nine directors were expected, and nine directors were present. Among them, Directors Liu Gexin, Liu Sichuan, He Guosheng, Zheng Changyan, and Independent Director Ren Shichou attended the meeting in person. Directors Ge Junyou, Zhou Xian, and Independent Directors Gao Jinbo and Wang Fuqing attended the meeting via teleconference. Senior management personnel of the Company attended the meeting. The convening of the meeting complied with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), relevant laws, administrative regulations, departmental rules, normative documents, and the Company's Articles of Association. The resolutions made were legal and valid.
The meeting was presided over by Mr. Liu Gexin, Chairman of the Board. The attending directors deliberated and voted on the following proposals, forming the following resolutions:
I. With 9 votes in favor, 0 votes against, and 0 abstentions, the Proposal on the 2025 Board of Directors Work Report was deliberated and approved. The detailed content of the Company's 2025 Board of Directors Work Report can be found in the relevant section of the Company's "2025 Annual Report." This report was published in its entirety on April 3, 2026, on the designated information disclosure website of the Company, CNINFO (www.cninfo.com.cn). This proposal needs to be submitted to the Company's shareholders' meeting for deliberation.
II. With 9 votes in favor, 0 votes against, and 0 abstentions, the Proposal on the 2025 General Manager Work Report was deliberated and approved. The detailed content of the Company's 2025 General Manager Work Report can be found in the relevant section of the Company's "2025 Annual Report." The full text of the "2025 Annual Report" was published on April 3, 2026, on the Company's designated information disclosure website, CNINFO (www.cninfo.com.cn).
III. With 9 votes in favor, 0 votes against, and 0 abstentions, the Proposal on the Self-Assessment of Independent Directors' Independence in 2025 was deliberated and approved. The Board of Directors has evaluated the independence of the independent directors for 2025 and issued a special opinion. For details, please refer to the "Special Opinion of the Board of Directors on the Self-Assessment of Independent Directors' Independence" disclosed by the Company on CNINFO (www.cninfo.com.cn).
IV. With 9 votes in favor, 0 votes against, and 0 abstentions, the Proposal on Deliberating the Company's 2025 Annual Report and Summary was deliberated and approved. The full text of the 2025 Annual Report and its summary can be found on the Company's designated information disclosure website, CNINFO (www.cninfo.com.cn). The annual report summary was also published on April 3, 2025, in the Securities Times, Shanghai Securities News, Securities Daily, and China Securities Journal. This proposal was deliberated and approved by the Board's Audit Committee and Strategy Committee before being submitted to the Board of Directors for deliberation. This proposal needs to be submitted to the Company's shareholders' meeting for deliberation.